Probiotics, prebiotics and colorectal cancer prevention
Abstract Colorectal cancer (CRC), the third major cause of mortality among various cancer types in United States, has been increasing in developing countries due to varying diet and dietary habits and occupational hazards. Recent evidences showed that composition of gut microbiota could be associate...
Gespeichert in:
| Veröffentlicht in: | Baillière's best practice & research. Clinical gastroenterology 2016-02, Vol.30 (1), p.119-131 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 131 |
|---|---|
| container_issue | 1 |
| container_start_page | 119 |
| container_title | Baillière's best practice & research. Clinical gastroenterology |
| container_volume | 30 |
| creator | Ambalam, Padma, PhD Raman, Maya, PhD Purama, Ravi Kiran, PhD Doble, Mukesh, PhD |
| description | Abstract Colorectal cancer (CRC), the third major cause of mortality among various cancer types in United States, has been increasing in developing countries due to varying diet and dietary habits and occupational hazards. Recent evidences showed that composition of gut microbiota could be associated with the development of CRC and other gut dysbiosis. Modulation of gut microbiota by probiotics and prebiotics, either alone or in combination could positively influence the cross-talk between immune system and microbiota, would be beneficial in preventing inflammation and CRC. In this review, role of probiotics and prebiotics in the prevention of CRC has been discussed. Various epidemiological and experimental studies, specifically gut microbiome research has effectively improved the understanding about the role of probiotics and microbial treatment as anticarcinogenic agents. A few human studies support the beneficial effect of probiotics and prebiotics; hence, comprehensive understanding is urgent to realize the clinical applications of probiotics and prebiotics in CRC prevention. |
| doi_str_mv | 10.1016/j.bpg.2016.02.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785241283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521691816000135</els_id><sourcerecordid>1779427734</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-fb2c538980d82fabde55b8289cc0050bf24bb0e15f6b8a5d4eebd25bcdb6812f3</originalsourceid><addsrcrecordid>eNqNkktrHDEQhIVJsB0nP8CXsJCLD5lJSzPSSBgMxuQFhgSSnIUePUGb2dFamjX430di1wn4EHLqPnxV0FVNyDmFlgIV79at3f5sWVlbYC2AOiKnlHesoYqKZ3VntBGKyhPyIuc1QCGVOiYnbIBeKuhOyfA1RRviElx-u9omPOwrM_uVi1NM6BYzrZyZHaYK3OO8hDi_JM9HM2V8dZhn5MeH999vPjW3Xz5-vrm-bVwv1NKMljneSSXBSzYa65FzK5lUzgFwsCPrrQWkfBRWGu57ROsZt85bISkbuzNysffdpni3w7zoTcgOp8nMGHdZ00Fy1lMmu_9AB9WzYej6gr55gq7jLs3lkGoIAwgx8ELRPeVSzDnhqLcpbEx60BR0LUCvdSlA1wI0MF0KKJrXB-ed3aD_o3hMvACXewBLavcBk84uYEnXh5q19jH80_7qidpNYQ7OTL_wAfPfK3QuAv2tfkB9ACpq-R3vfgOis6my</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780706675</pqid></control><display><type>article</type><title>Probiotics, prebiotics and colorectal cancer prevention</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ambalam, Padma, PhD ; Raman, Maya, PhD ; Purama, Ravi Kiran, PhD ; Doble, Mukesh, PhD</creator><creatorcontrib>Ambalam, Padma, PhD ; Raman, Maya, PhD ; Purama, Ravi Kiran, PhD ; Doble, Mukesh, PhD</creatorcontrib><description>Abstract Colorectal cancer (CRC), the third major cause of mortality among various cancer types in United States, has been increasing in developing countries due to varying diet and dietary habits and occupational hazards. Recent evidences showed that composition of gut microbiota could be associated with the development of CRC and other gut dysbiosis. Modulation of gut microbiota by probiotics and prebiotics, either alone or in combination could positively influence the cross-talk between immune system and microbiota, would be beneficial in preventing inflammation and CRC. In this review, role of probiotics and prebiotics in the prevention of CRC has been discussed. Various epidemiological and experimental studies, specifically gut microbiome research has effectively improved the understanding about the role of probiotics and microbial treatment as anticarcinogenic agents. A few human studies support the beneficial effect of probiotics and prebiotics; hence, comprehensive understanding is urgent to realize the clinical applications of probiotics and prebiotics in CRC prevention.</description><identifier>ISSN: 1521-6918</identifier><identifier>EISSN: 1532-1916</identifier><identifier>DOI: 10.1016/j.bpg.2016.02.009</identifier><identifier>PMID: 27048903</identifier><identifier>CODEN: BPRCB6</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Anticarcinogenic Agents - therapeutic use ; Bifidobacteria ; Colorectal cancer ; Colorectal Neoplasms - prevention & control ; Diet ; Gastroenterology and Hepatology ; Gastrointestinal Microbiome - physiology ; Gut microbiota ; Humans ; Immune System - physiology ; Kinases ; Lactobacillus ; Prebiotics ; Prebiotics - microbiology ; Probiotics ; Probiotics - therapeutic use ; Rodents ; Studies ; Synbiotics</subject><ispartof>Baillière's best practice & research. Clinical gastroenterology, 2016-02, Vol.30 (1), p.119-131</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Feb 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-fb2c538980d82fabde55b8289cc0050bf24bb0e15f6b8a5d4eebd25bcdb6812f3</citedby><cites>FETCH-LOGICAL-c469t-fb2c538980d82fabde55b8289cc0050bf24bb0e15f6b8a5d4eebd25bcdb6812f3</cites><orcidid>0000-0002-1463-6312</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1521691816000135$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27048903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ambalam, Padma, PhD</creatorcontrib><creatorcontrib>Raman, Maya, PhD</creatorcontrib><creatorcontrib>Purama, Ravi Kiran, PhD</creatorcontrib><creatorcontrib>Doble, Mukesh, PhD</creatorcontrib><title>Probiotics, prebiotics and colorectal cancer prevention</title><title>Baillière's best practice & research. Clinical gastroenterology</title><addtitle>Best Pract Res Clin Gastroenterol</addtitle><description>Abstract Colorectal cancer (CRC), the third major cause of mortality among various cancer types in United States, has been increasing in developing countries due to varying diet and dietary habits and occupational hazards. Recent evidences showed that composition of gut microbiota could be associated with the development of CRC and other gut dysbiosis. Modulation of gut microbiota by probiotics and prebiotics, either alone or in combination could positively influence the cross-talk between immune system and microbiota, would be beneficial in preventing inflammation and CRC. In this review, role of probiotics and prebiotics in the prevention of CRC has been discussed. Various epidemiological and experimental studies, specifically gut microbiome research has effectively improved the understanding about the role of probiotics and microbial treatment as anticarcinogenic agents. A few human studies support the beneficial effect of probiotics and prebiotics; hence, comprehensive understanding is urgent to realize the clinical applications of probiotics and prebiotics in CRC prevention.</description><subject>Anticarcinogenic Agents - therapeutic use</subject><subject>Bifidobacteria</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - prevention & control</subject><subject>Diet</subject><subject>Gastroenterology and Hepatology</subject><subject>Gastrointestinal Microbiome - physiology</subject><subject>Gut microbiota</subject><subject>Humans</subject><subject>Immune System - physiology</subject><subject>Kinases</subject><subject>Lactobacillus</subject><subject>Prebiotics</subject><subject>Prebiotics - microbiology</subject><subject>Probiotics</subject><subject>Probiotics - therapeutic use</subject><subject>Rodents</subject><subject>Studies</subject><subject>Synbiotics</subject><issn>1521-6918</issn><issn>1532-1916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkktrHDEQhIVJsB0nP8CXsJCLD5lJSzPSSBgMxuQFhgSSnIUePUGb2dFamjX430di1wn4EHLqPnxV0FVNyDmFlgIV79at3f5sWVlbYC2AOiKnlHesoYqKZ3VntBGKyhPyIuc1QCGVOiYnbIBeKuhOyfA1RRviElx-u9omPOwrM_uVi1NM6BYzrZyZHaYK3OO8hDi_JM9HM2V8dZhn5MeH999vPjW3Xz5-vrm-bVwv1NKMljneSSXBSzYa65FzK5lUzgFwsCPrrQWkfBRWGu57ROsZt85bISkbuzNysffdpni3w7zoTcgOp8nMGHdZ00Fy1lMmu_9AB9WzYej6gr55gq7jLs3lkGoIAwgx8ELRPeVSzDnhqLcpbEx60BR0LUCvdSlA1wI0MF0KKJrXB-ed3aD_o3hMvACXewBLavcBk84uYEnXh5q19jH80_7qidpNYQ7OTL_wAfPfK3QuAv2tfkB9ACpq-R3vfgOis6my</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Ambalam, Padma, PhD</creator><creator>Raman, Maya, PhD</creator><creator>Purama, Ravi Kiran, PhD</creator><creator>Doble, Mukesh, PhD</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-1463-6312</orcidid></search><sort><creationdate>20160201</creationdate><title>Probiotics, prebiotics and colorectal cancer prevention</title><author>Ambalam, Padma, PhD ; Raman, Maya, PhD ; Purama, Ravi Kiran, PhD ; Doble, Mukesh, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-fb2c538980d82fabde55b8289cc0050bf24bb0e15f6b8a5d4eebd25bcdb6812f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anticarcinogenic Agents - therapeutic use</topic><topic>Bifidobacteria</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - prevention & control</topic><topic>Diet</topic><topic>Gastroenterology and Hepatology</topic><topic>Gastrointestinal Microbiome - physiology</topic><topic>Gut microbiota</topic><topic>Humans</topic><topic>Immune System - physiology</topic><topic>Kinases</topic><topic>Lactobacillus</topic><topic>Prebiotics</topic><topic>Prebiotics - microbiology</topic><topic>Probiotics</topic><topic>Probiotics - therapeutic use</topic><topic>Rodents</topic><topic>Studies</topic><topic>Synbiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ambalam, Padma, PhD</creatorcontrib><creatorcontrib>Raman, Maya, PhD</creatorcontrib><creatorcontrib>Purama, Ravi Kiran, PhD</creatorcontrib><creatorcontrib>Doble, Mukesh, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ambalam, Padma, PhD</au><au>Raman, Maya, PhD</au><au>Purama, Ravi Kiran, PhD</au><au>Doble, Mukesh, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotics, prebiotics and colorectal cancer prevention</atitle><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle><addtitle>Best Pract Res Clin Gastroenterol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>30</volume><issue>1</issue><spage>119</spage><epage>131</epage><pages>119-131</pages><issn>1521-6918</issn><eissn>1532-1916</eissn><coden>BPRCB6</coden><abstract>Abstract Colorectal cancer (CRC), the third major cause of mortality among various cancer types in United States, has been increasing in developing countries due to varying diet and dietary habits and occupational hazards. Recent evidences showed that composition of gut microbiota could be associated with the development of CRC and other gut dysbiosis. Modulation of gut microbiota by probiotics and prebiotics, either alone or in combination could positively influence the cross-talk between immune system and microbiota, would be beneficial in preventing inflammation and CRC. In this review, role of probiotics and prebiotics in the prevention of CRC has been discussed. Various epidemiological and experimental studies, specifically gut microbiome research has effectively improved the understanding about the role of probiotics and microbial treatment as anticarcinogenic agents. A few human studies support the beneficial effect of probiotics and prebiotics; hence, comprehensive understanding is urgent to realize the clinical applications of probiotics and prebiotics in CRC prevention.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>27048903</pmid><doi>10.1016/j.bpg.2016.02.009</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-1463-6312</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6918 |
| ispartof | Baillière's best practice & research. Clinical gastroenterology, 2016-02, Vol.30 (1), p.119-131 |
| issn | 1521-6918 1532-1916 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1785241283 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anticarcinogenic Agents - therapeutic use Bifidobacteria Colorectal cancer Colorectal Neoplasms - prevention & control Diet Gastroenterology and Hepatology Gastrointestinal Microbiome - physiology Gut microbiota Humans Immune System - physiology Kinases Lactobacillus Prebiotics Prebiotics - microbiology Probiotics Probiotics - therapeutic use Rodents Studies Synbiotics |
| title | Probiotics, prebiotics and colorectal cancer prevention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotics,%20prebiotics%20and%20colorectal%20cancer%20prevention&rft.jtitle=Bailli%C3%A8re's%20best%20practice%20&%20research.%20Clinical%20gastroenterology&rft.au=Ambalam,%20Padma,%20PhD&rft.date=2016-02-01&rft.volume=30&rft.issue=1&rft.spage=119&rft.epage=131&rft.pages=119-131&rft.issn=1521-6918&rft.eissn=1532-1916&rft.coden=BPRCB6&rft_id=info:doi/10.1016/j.bpg.2016.02.009&rft_dat=%3Cproquest_cross%3E1779427734%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780706675&rft_id=info:pmid/27048903&rft_els_id=S1521691816000135&rfr_iscdi=true |